We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » TEVA OPPOSES 10-YEAR DATA EXCLUSIVITY PROVISION FOR ISRAEL
TEVA OPPOSES 10-YEAR DATA EXCLUSIVITY PROVISION FOR ISRAEL
May 4, 2004
Israeli generic firm Teva Pharmaceutical is objecting to what it contends is pressure from U.S. trade officials that Israel adopt a 10-year data exclusivity period for drugs — a period twice as long as the exclusivity period in the U.S.